Nama's AI scorecard currently rates Elevance Health Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ELV's P/E ratio?

Elevance Health trades at a trailing price-to-earnings ratio of 14.0.

When does ELV report earnings?

Elevance Health's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $2.07.

What is the ELV price target?

The median analyst price target from 21 analysts is $492.00, with a range of $406.00 – $523.00.

Is ELV Shariah compliant?

Nama's AAOIFI-style screen reads Elevance Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does ELV pay a dividend?

Yes — Elevance Health's dividend yield is 1.6%.

Nama Insights

Elevance Health (ELV)

Healthcare · Healthcare Plans · NYSE

S&P 500

Elevance Health (ELV) is a Healthcare company in the Healthcare Plans industry. It has a market capitalization of $91.96B, a trailing price-to-earnings ratio of 14.0 and a free-cash-flow yield of 3.3%. Over the most recent reported fiscal year, revenue grew 12.6% and free cash flow per share fell 27.7%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +28.6% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-25.0%

How far the last close sits under the highest price of the past five years.

Market cap	$91.96B
Trailing P/E	14.0
Price / book	2.1
Price / sales	0.5
FCF yield	3.3%
Dividend yield	1.6%
Gross margin	26.4%
Operating margin	4.2%
Net margin	2.5%
Revenue growth (YoY)	+12.6%
Revenue growth (3-yr annual)	+8.3%
EPS growth (YoY)	-8.5%
FCF/share growth (YoY)	-27.7%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Healthcare Plans

ELV earnings

Next report: Jan 28, 2027 (Q4 2026, EPS estimate $2.07). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 21, 2026	$6.99	$4.69	+49.0%	$51.43B
Q2 2026	Jul 15, 2026	$7.45	$6.21	+20.0%	$50.47B
Q1 2026	Apr 22, 2026	$12.58	$10.81	+16.4%	$50.18B
Q4 2025	Jan 28, 2026	$3.33	$3.09	+7.8%	$49.75B

ELV analyst price target

Median target $492.00 from 21 analysts, ranging $406.00 – $523.00.

Healthcare Plans peers

Ticker	Company	Market cap	P/E
UNH	UnitedHealth Group	$353.17B	19.3
CVS	CVS Health	$107.28B	10.1
CI	Cigna Group	$77.58B	9.3
HUM	Humana	$52.08B	32.7
CNC	Centene	$34.53B	13.2
MOH	Molina Healthcare	$10.87B	104.5
OSCR	Oscar Health	$9.46B	12.7
PGNY	Progyny	$2.58B	17.0

Explore live ELV data on Nama Insights →

Recent Congressional trades

Elevance Health trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Lisa McClain	House	Sell	$1,001 - $15,000	Sep 12, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 12, 2025
Valerie Hoyle	House	Sell	$1,001 - $15,000	Sep 12, 2025
Valerie Hoyle	House	Buy	$1,001 - $15,000	Sep 12, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Jefferson Shreve	House	Sell	$15,001 - $50,000	Jun 22, 2025
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Jun 6, 2025
Rob Bresnahan	House	Sell	$15,001 - $50,000	May 31, 2025
Dan Newhouse	House	Sell	$1,001 - $15,000	May 16, 2025
Gilbert Cisneros	House	Buy	$1,001 - $15,000	May 6, 2025

ELV FAQ

Is ELV a buy?: Nama's AI scorecard currently rates Elevance Health Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ELV's P/E ratio?: Elevance Health trades at a trailing price-to-earnings ratio of 14.0.
When does ELV report earnings?: Elevance Health's next scheduled report is on Jan 28, 2027. Analysts expect EPS of $2.07.
What is the ELV price target?: The median analyst price target from 21 analysts is $492.00, with a range of $406.00 – $523.00.
Is ELV Shariah compliant?: Nama's AAOIFI-style screen reads Elevance Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does ELV pay a dividend?: Yes — Elevance Health's dividend yield is 1.6%.